Core Viewpoint - Kangchen Pharmaceutical's stock price has shown a slight increase of 2.01% this year, but has experienced a decline of 9.81% over the past 20 days and 22.69% over the past 60 days, indicating volatility in its stock performance [2]. Group 1: Stock Performance - As of January 5, Kangchen Pharmaceutical's stock price reached 40.55 CNY per share, with a trading volume of 30.14 million CNY and a turnover rate of 0.47%, resulting in a total market capitalization of 6.448 billion CNY [1]. - The stock has increased by 2.01% year-to-date, with a minor increase of 0.22% over the last five trading days, while it has seen significant declines of 9.81% over the last 20 days and 22.69% over the last 60 days [2]. Group 2: Company Overview - Kangchen Pharmaceutical, established on September 3, 2003, and listed on August 27, 2018, is located in Beijing and focuses on innovative drug research and development, integrating R&D, production, and sales [2]. - The company's main business revenue is derived from Suling (70.77%), Salmon Calcitonin (29.15%), and other sources (0.09%) [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the sub-sector of other biological products, and is associated with concepts such as monkeypox, biopharmaceuticals, innovative drugs, venture capital, and small-cap stocks [2]. Group 3: Financial Performance - For the period from January to September 2025, Kangchen Pharmaceutical reported a revenue of 692 million CNY, reflecting a year-on-year growth of 7.10%, and a net profit attributable to shareholders of 128 million CNY, which is a 13.19% increase compared to the previous year [2]. - Since its A-share listing, the company has distributed a total of 437 million CNY in dividends, with 175 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders for Kangchen Pharmaceutical reached 10,700, an increase of 7.18% from the previous period, with an average of 14,806 circulating shares per shareholder, a decrease of 6.12% [2]. - Notable new institutional shareholders include Qianhai Kaiyuan HuGangShen Advantage Selection Mixed A (holding 1.7445 million shares), Qianhai Kaiyuan China Scarce Asset Mixed A (holding 1.6075 million shares), and others, while several previous major shareholders have exited the top ten list [3].

1月5日，步长制药盘中上涨2.05%，截至10:11，报15.96元/股，成交3822.57万元，换手率0.23%，总市 值168.31亿元。 资料显示，山东步长制药股份有限公司位于山东省菏泽市牡丹区中华西路369号，成立日期2001年5月10 日，上市日期2016年11月18日，公司主营业务涉及中成药的研发、生产和销售。主营业务收入构成为： 中成药82.34%，化学药10.08%，医疗器械6.61%，其他0.97%。 机构持仓方面，截止2025年9月30日，步长制药十大流通股东中，香港中央结算有限公司位居第六大流 通股东，持股2038.71万股，相比上期增加851.27万股。南方中证500ETF（510500）位居第九大流通股 东，持股804.20万股，相比上期减少14.45万股。 步长制药所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：疫苗、中药、医药电商、创 新药、养老产业等。 责任编辑：小浪快报 截至9月30日，步长制药股东户数5.11万，较上期减少7.36%；人均流通股20641股，较上期增加2.92%。 2025年1月-9月，步长制药实现营业收入84.69亿元，同比减少0.54%；归母 ...

1月5日，诺诚健华盘中上涨2.05%，截至10:09，报20.94元/股，成交5700.76万元，换手率1.03%，总市 值369.52亿元。 资金流向方面，主力资金净流出615.30万元，特大单买入145.09万元，占比2.55%，卖出291.78万元，占 比5.12%；大单买入1265.91万元，占比22.21%，卖出1734.52万元，占比30.43%。 诺诚健华今年以来股价涨2.05%，近5个交易日跌3.50%，近20日跌15.70%，近60日跌21.69%。 资料显示，诺诚健华医药有限公司位于北京市昌平区中关村生命科学园生命园路8号院8号楼，成立日期 2015年11月3日，上市日期2022年9月21日，公司主营业务涉及诺诚健华医药有限公司是一家主要从事生 物医药的研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求 的领域，其产品管线包括ICP-022、ICP-B04、ICP-490、ICP-192、ICP-723、ICP-022等。该公司主要在 中国和美国开展业务。主营业务收入构成为：药品销售87.67%，技术授权12.04%，检测服务0.15%，研 发服务0.15% ...

1月5日，一品红盘中上涨2.06%，截至09:52，报34.24元/股，成交7085.72万元，换手率0.50%，总市值 154.66亿元。 资金流向方面，主力资金净流入105.71万元，特大单买入0.00元，占比0.00%，卖出190.98万元，占比 2.70%；大单买入1182.72万元，占比16.69%，卖出886.02万元，占比12.50%。 一品红今年以来股价涨2.06%，近5个交易日跌4.01%，近20日跌28.96%，近60日跌39.17%。 机构持仓方面，截止2025年9月30日，一品红十大流通股东中，香港中央结算有限公司位居第七大流通 股东，持股414.96万股，为新进股东。广发医疗保健股票A（004851）位居第九大流通股东，持股 304.52万股，为新进股东。富国精准医疗灵活配置混合A（005176）位居第十大流通股东，持股281.13 万股，为新进股东。易方达医疗保健行业混合A（110023）退出十大流通股东之列。 责任编辑：小浪快报 一品红所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：猴痘概念、肝炎治疗、疫 苗、创新药、中药等。 截至11月30日，一品红股东户数2. ...

Core Viewpoint - The company, YuanDa Pharmaceutical, has made significant advancements in innovative products, showcasing its "self-research + introduction" strategy in the fields of nuclear medicine, traditional Chinese medicine for depression, and emergency treatments, indicating a strong potential for sustainable growth in the innovative drug sector [1][16]. Group 1: Innovative Product Developments - The company achieved success in its Phase II clinical trial for an innovative traditional Chinese medicine for depression [1]. - The FDA approved the company's self-researched FAP-targeted nuclear medicine for clinical research, while an introduced prostate cancer diagnostic nuclear medicine reached the end of its Phase III clinical trial in China, indicating imminent commercialization [1][2]. - The company launched the world's first epinephrine nasal spray for emergency treatment of type I allergic reactions in China, enhancing its cardiovascular emergency product line [1][14]. Group 2: Nuclear Medicine Advancements - The GPN01530 nuclear medicine, targeting FAP, has shown superior performance compared to current cancer diagnostic products, with a sensitivity of 80%-90% for certain cancers, potentially replacing the mainstream product 18F-FDG [2][3]. - TLX591-CDx, a prostate cancer diagnostic nuclear medicine, achieved a positive top-line result in its Phase III clinical trial, demonstrating a 100% positive predictive value for recurrent prostate cancer [4][5]. - The company has a robust pipeline with 16 innovative products in the registration phase, covering various radioactive isotopes and cancer types, indicating a comprehensive approach to nuclear medicine [7]. Group 3: Strategic Initiatives - The company employs a dual strategy of "self-research + global introduction," enhancing its innovation capabilities and product offerings in the nuclear medicine sector [6][10]. - The establishment of a comprehensive global industrial network, including R&D and production bases in Boston and Chengdu, supports the company's competitive edge in the nuclear medicine market [10][13]. - The company's proactive "China-US dual reporting" strategy accelerates drug approvals in major markets, enhancing the international market value of its products [10]. Group 4: Financial Performance and Market Outlook - The company reported a significant increase in revenue from innovative and barrier products, accounting for approximately 51% of total revenue, reflecting a year-on-year increase of 14.9 percentage points [16]. - The global nuclear medicine market is projected to grow from approximately $10.65 billion in 2023 to $31.44 billion by 2033, with a compound annual growth rate of about 11.45%, positioning the company to benefit from this market expansion [13]. - The company's market capitalization has doubled since the beginning of the year, indicating strong market recognition of its innovative strategy and growth potential [16].

本周（1月5日至1月11日），中国方面，2025年12月（下称12月）CPI数据、12月外汇储备数据将公布；央行公开市场将有13236亿元逆回购到 期；2026（第十六届）中国互联网产业年会将于1月7日至8日在北京召开；沪深两市超1600亿元市值限售股解禁。 国际方面，欧元区发布12月CPI、12月PMI数据，美国12月非农就业报告，国际消费类电子产品展览会（CES2026）将于1月6日至9日在美国举 办。 1月5日（周一） 韩国总统李在明于1月4日至7日对中国进行国事访问 国新办1月5日就长江经济带发展十年工作进展和成效举行新闻发布会 中国央行4823亿元7天期逆回购到期 国内航线燃油附加费1月5日起下调 中证指数有限公司将首次发布中证全债指数（全价）等15条债券全价指数 荣耀Power2手机将发布 华硕向客户发出公告，1月5日起即将调整部分产品价格 1月6日（周二） 欧元区12月PMI数据 国际消费类电子产品展览会（CES2026）将于1月6日至9日在美国举办 国新办将就推进绿色消费有关情况举行新闻发布会 联想集团将与英伟达联合重磅发布一款企业级AI产品 1月7日（周三） 欧元区12月CPI 美国12月A ...

Group 1 - The year 2025 was a transformative period for fund investors, marked by a journey of cognitive upgrades and emotional adjustments, leading to a more rational and determined mindset as they approach 2026 [1] - The capital market in 2025 demonstrated resilience amidst volatility, with investors like Zhao maintaining high positions in technology and metals, while others like Li faced challenges due to emotional decision-making [2][3] - Investors are shifting from chasing trends to focusing on asset allocation and rational decision-making, recognizing the importance of discipline and risk management in navigating market complexities [5] Group 2 - Investors are planning to optimize their portfolio structures in 2026, with strategies such as increasing investments in index funds and concentrating on high-performing funds to enhance returns [4] - The experiences of investors in 2025 have led to a more pragmatic approach, emphasizing the need for a balanced allocation and a focus on quality assets to navigate potential market fluctuations [4][5] - The overall sentiment among investors is moving towards a long-term perspective, with an understanding that investment is a continuous journey that requires patience and respect for market dynamics [5]

市场也给不少"追风者"上了一课。罗女士曾试图通过"广撒网"的方式捕捉投资机会，持仓一度超过20只 基金，涵盖了人工智能、创新药等热门赛道。这种"基金超市"模式在普涨行情下收益可观，而当行情轮 动加快时，却陷入了顾此失彼的窘境。 李先生的经历则更具代表性。面对2025年的上涨，他起初因恐高而犹豫，却在市场情绪持续高涨时，在 阶段性高点重仓买入，随后承受了回调损失。他坦言，自己陷入了"越涨越不敢买，越不敢买越涨"的纠 结，结果在高位匆忙入场。此后，李先生并未频繁操作，面对账户的一片绿色，仍坚持自己的节奏。他 那句"宁可不动，也不要乱动"，不仅是对2025年的反思，也是对市场复杂性的深刻领悟。 沉淀与蜕变：优化配置结构 ● 本报记者 郝健 刚刚过去的2025年对于每一位基金投资者而言，不仅是基金净值的起伏曲线，更是一段认知升级、心态 博弈与自我和解的心路历程。从年初的谨慎试探，到年中的积极参与，再到年末的理性沉淀，一些基民 经历了资本市场的磨炼，逐渐摸索出适合自己的投资方法。面对已经开启的2026年，基民的心态少了一 分盲目，多了一分冷静与笃定。 迷雾与觉醒：复苏行情下的众生相 2025年的资本市场，在波动中展现韧 ...

要闻速递 外交部发言人就美国强行控制委内瑞拉总统马杜罗夫妇答记者问 4日，外交部发言人就美国强行控制委内瑞拉总统马杜罗夫妇答记者问。问：据报道，1月3 日，美国派兵强行控制委内瑞拉总统马杜罗夫妇并移送出境。多国政府发声对此表示反对。中 方对此有何评论？答：中方对美方强行控制马杜罗总统夫妇并移送出境表示严重关切，美方行 径明显违反国际法和国际关系基本准则，违反《联合国宪章》宗旨和原则。中方呼吁美方确保 马杜罗总统夫妇人身安全，立即释放马杜罗总统和夫人，停止颠覆委内瑞拉政权，通过对话谈 判解决问题。详情>> 韩国总统李在明抵达北京 开启就任后首次对华国事访问 4日下午，韩国总统李在明乘机抵达北京首都国际机场，开启为期4天的访华行程。此访是李在 明总统就任后首次访华，也是韩国总统时隔6年再次访华。 元旦假期海南离岛免税购物金额7.12亿元 据海口海关统计，元旦假期期间（2026年1月1日至3日），海口海关共监管离岛免税商品销售 44.2万件，同比增长52.4%；购物人数8.35万人次，同比增长60.6%；购物金额7.12亿元，同比 增长128.9%。 创新高！去年我国批准创新药76个 对外授权破千亿美元 据国家药监 ...

《瑞博生物通过港交所 IPO 聆讯，上 市在即—行业周报》-2025.12.28 《推荐 CXO+科研服务板块的估值切 换机会—行业周报》-2025.12.21 《2025 国谈结果公布，关注相关公司 投资机会—行业周报》-2025.12.14 医药生物 医药生物 2026 年 01 月 04 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 38% 2025-01 2025-05 2025-09 医药生物 沪深300 创新驱动下，2025 年医药各细分赛道牛股频出 ——行业周报 相关研究报告 | 余汝意（分析师） | 聂媛媛（联系人） | | --- | --- | | yuruyi@kysec.cn | nieyuanyuan@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124050002 | nieyuanyuan@kysec.cn 证书编号：S0790124050002 创新驱动下，2025 年医药各细分赛道牛股频出 回顾 2025 年医药细分赛道表现情况看，各个板块均涌现了多个翻倍以上的牛股。 其中，整体表现 ...